Was testosterone replacement non-inferior to placebo for cardiovascular safety in men with hypogonadism and high cardiovascular risk?

In TRAVERSE, testosterone replacement was non-inferior to placebo for major adverse cardiac events in middle-aged and older men with hypogonadism and high cardiovascular risk.

Randomised trial · New England Journal of Medicine 2023

Reference: Lincoff AM, Bhasin S, Flevaris P, et al. N Engl J Med. 2023;389(2):107-117. PMID: 37326322. https://pubmed.ncbi.nlm.nih.gov/37326322/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en